Novel Therapeutic Approaches for Cutaneous Angiosarcoma, Particularly Focusing on Immune Checkpoint Inhibitors.

Although the difference did not reach statistical significance, a trend toward improved disease control was observed in the TMB-high group.

also in 111,027 other papers